Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

inical study of LBH589 in combination with INC424 in JAK2V617F-driven disease (ASH abstract #798; December 12, 4:30 – 6:00PM).

About everolimus
In the US, Afinitor® (everolimus) tablets is approved for the treatment of progressive neuroendocrine tumors of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease and for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. The US Food and Drug Administration (FDA) determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

Afinitor is also approved in the US to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.

In the US, everolimus is available from Novartis in different dosage strengths and for different uses in non-oncology patient populations under the trade name Zortress®. Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. As an investigational compound, the safety and efficacy profile of everolimus has not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for additional indications anywhere else in the world.

'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... OREX ), a biopharmaceutical company focused on the ... results for its second quarter ended June 30, 2008, ... announcement will be followed,by a live webcast and conference ... will host the call and webcast to discuss results,for ...
... IRIX ) today announced that it will release ... on Tuesday, August,12, 2008. In conjunction with the release, ... community at 5:00 p.m. Eastern Time on,Tuesday, August 12, ... other,business developments., Interested parties may access the live ...
... Lai-Goldman, Chief Medical Officer of LabCorp and Jack Ballantyne, ... ... Team, CARLSBAD, Calif., Aug. 5 GenVault Corporation ... Lai-Goldman and,Dr. Jack Ballantyne, have joined its Scientific Advisory ...
Cached Biology Technology:Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008 2GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... scientific advances across the spectrum of science, technology, ... explained through engaging table-top exhibits at the Coalition ... & Reception. The exhibition/reception will be held 5:30 ... Rooms B338-340 of the Rayburn House Office Building ...
... to prevent bacterial infections from taking hold. Writing in ... Parks and colleagues describe how they used enzymes against ... Pseudomonas aeruginosa bacteria from building a protective ... immune mechanisms and antibiotics. When the body,s defence ...
... researchers have tried and failed to develop an HIV vaccine, ... "super antibodies" to fend off the virus before it takes ... to produce in people. Now, in research to be published ... Rockefeller University have laid out a new approach. They have ...
Cached Biology News:Science returns to the Capitol Hill spotlight at March 24 exhibition 2Science returns to the Capitol Hill spotlight at March 24 exhibition 3Science returns to the Capitol Hill spotlight at March 24 exhibition 4A natural approach for HIV vaccine 2A natural approach for HIV vaccine 3